Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nusulin Sugar Balance is a multi-ingredient nutraceutical formulation developed by researchers at the Chinese PLA General Hospital (301 Hospital) for the management of type 2 diabetes mellitus. The product is designed to improve glycemic control through a synergistic blend of botanical extracts and essential minerals. Its primary components include *Cinnamomum cassia* (cinnamon) extract, which contains polyphenols that may mimic insulin activity and enhance glucose uptake; *Gymnema sylvestre* extract, which is thought to reduce intestinal sugar absorption and support pancreatic beta-cell function; and chromium picolinate, which facilitates insulin binding to its receptor. Clinical research conducted at the PLA General Hospital has investigated its efficacy in reducing HbA1c and fasting blood glucose levels in diabetic patients. It is typically used as a complementary therapy alongside conventional antidiabetic medications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Nusulin Sugar Balance.